Moleculin Biotech, Inc. (MBRX)

$2.7

+0.12

(+4.45%)▲

Live

Performance

  • $2.63
    $2.82
    $2.70
    downward going graph

    2.59%

    Downside

    Day's Volatility :6.73%

    Upside

    4.25%

    downward going graph
  • $2.12
    $15.75
    $2.70
    downward going graph

    21.67%

    Downside

    52 Weeks Volatility :86.57%

    Upside

    82.86%

    downward going graph

Returns

PeriodMoleculin Biotech, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-36.01%
3.6%
0.0%
6 Months
-39.88%
10.2%
0.0%
1 Year
-66.92%
19.6%
0.0%
3 Years
-93.91%
16.8%
-23.0%

Highlights

Market Capitalization
6.7M
Book Value
$6.91
Earnings Per Share (EPS)
-11.73
PEG Ratio
0.0
Wall Street Target Price
31.67
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-47.68%
Return On Equity TTM
-86.82%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-27.6M
Diluted Eps TTM
-11.73
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-7.48
EPS Estimate Next Year
-5.87
EPS Estimate Current Quarter
-2.51
EPS Estimate Next Quarter
-2.31

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Moleculin Biotech, Inc.(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 1072.96%

Current $2.70
Target $31.67

Technicals Summary

Sell

Neutral

Buy

Moleculin Biotech, Inc. is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Moleculin Biotech, Inc.
Moleculin Biotech, Inc.
-4.61%
-39.88%
-66.92%
-93.91%
-97.34%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.28%
10.06%
24.53%
74.0%
232.45%
Novo Nordisk A/s
Novo Nordisk A/s
-4.54%
-5.72%
21.59%
126.2%
349.01%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
8.87%
102.98%
82.67%
44.83%
241.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
5.0%
20.77%
31.37%
158.16%
163.17%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Moleculin Biotech, Inc.
Moleculin Biotech, Inc.
NA
NA
0.0
-7.48
-0.87
-0.48
NA
6.91
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.41
26.41
1.37
44.9
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.21
40.21
1.81
3.36
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.42
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.59
0.18
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Moleculin Biotech, Inc.
Moleculin Biotech, Inc.
Buy
$6.7M
-97.34%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.0B
232.45%
26.41
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$529.8B
349.01%
40.21
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$38.1B
241.09%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.7B
163.17%
32.84
-4.74%

Insights on Moleculin Biotech, Inc.

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 153.7%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 138.7%

Institutional Holdings

  • Armistice Capital, LLC

    5.48%

  • Vanguard Group Inc

    2.97%

  • LPL Financial Corp

    1.19%

  • Geode Capital Management, LLC

    0.69%

  • BlackRock Inc

    0.44%

  • ATTICUS WEALTH MANAGEMENT, LLC

    0.12%

Company Information

moleculin biotech, inc. is a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on discoveries made at m.d. anderson cancer center. our lead product candidate is annamycin, a phase ii clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as aml. we also have two pre-clinical small molecule portfolios, one of which is focused on the modulation of hard-to-target tumor cell signaling mechanisms and the recruitment of the patient’s own immune system. the other portfolio targets the metabolism of tumors.

Organization
Moleculin Biotech, Inc.
Employees
18
CEO
Mr. Walter V. Klemp
Industry
Health Technology

Discover More

FAQs